ClinicalTrials.gg
CompletedNCT04102553Updated Jun 29, 2021

F-18-PSMA-1007 Versus F-18-Fluorocholine PET in Patients With Biochemical Recurrence

A Phase 3 interventional study of F-18-PSMA-1007 and F-18-Fluorocholine in Prostate Cancer and Prostate Cancer Recurrent, sponsored by ABX advanced biochemical compounds GmbH. Completed at 6 sites in France. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-29.

Sponsored by ABX advanced biochemical compounds GmbH · Phase 3, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Mar 2019, registered Sep 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 509 studies in Prostatic Neoplasms with a site in France — 89 open to participants now, 154 under way, 50 of them phase 3. Prostatic Neoplasms · France.

Enrollment
193rd of 405
200 · median 185
Started
2019
with 26 others
Phase 3
143 of 509
19 open now
Registered
311th of 509
by date

Among the 509 studies in Prostatic Neoplasms with a site in France, this one is the 193rd largest by enrollment of the 405 interventional ones that give a count, is one of 27 that started in 2019, is one of 143 in phase 3, and was the 311th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

89 of the 509 studies in Prostatic Neoplasms with a site in France are open now. Recruiting first, the newest first:

84 more — sign in →

All 89 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 509 studies in Prostatic Neoplasms with a site in France, or all of them as a file.
02

Study summary

This study evaluates the diagnostic performance and safety of F-18-PSMA-1007 and F-18-Fluorocholine PET/CT imaging in patients with suspected recurrence of prostate cancer after previous definitive treatment.

03

Conditions studied

  • Prostate Cancer
  • Prostate Cancer Recurrent

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • male with original diagnosis of prostate carcinoma with prior definitive therapy
  • suspicion of recurrence (3 consecutive PSA rises and/or PSA rise by 2.0 ng/mL or more above nadir after radiotherapy or cryotherapy and/or PSA rise by greater than 0.2 ng/mL after prostatectomy)
  • of 6 months or more as judged by the investigator
  • willing and able to undergo all study procedures
  • in writing (dated and signed)

Exclusion criteria

Exclusion Criteria:

  • age: less than18 years
  • for F-18-Fluorocholine
  • contraindications for any of the ingredients of F-18-PSMA-1007
  • close affiliation with the site; e.g. first-degree relative of the investigator
  • at the time of enrolment into this study, participating in another therapeutic clinical trial or has completed study participation in another therapeutic clinical trial within 5 days of enrolment into this trial
  • having been previously enrolled in this clinical trial
  • mental conditions rendering the subject incapable to understand the nature, scope, and consequences of the trial
  • being clinically unstable or requiring emergency treatment
  • being considered a vulnerable person
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    F-18-PSMA-1007

    Patients will receive F-18-PSMA-1007 PET/CT first, followed by F-18-Fluorocholine PET/CT.

    Drug: F-18-PSMA-1007 · Drug: F-18-Fluorocholine

  • Active comparator
    F-18-Fluorocholine

    Patients will receive F-18-Fluorocholine PET/CT first, followed by F-18-PSMA-1007 PET/CT.

    Drug: F-18-PSMA-1007 · Drug: F-18-Fluorocholine

Interventions

  • DrugPSMA-1007 F-18Studies of PSMA-1007 F-18PSMA-1007 F-18 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will receive F-18-PSMA-1007 PET/CT and F-18-Fluorocholine PET/CT in randomized order.

  • DrugF-18-Fluorocholine

    Patients will receive F-18-PSMA-1007 PET/CT and F-18-Fluorocholine PET/CT in randomized order.

06

What researchers measure

Primary outcomes

  1. To compare detection rate of metastatic prostate cancer lesions of F-18-PSMA-1007 versus F-18-Fluorocholine

    Time frame: Within 6 months after PET/CT

07

Study locations

6 sites
  • Centre Jean Perrin Clermont-Ferrand
    Clermont-Ferrand, France
  • Centre Léon Bérard LUMEN
    Lyon, France
  • Hôpitaux de Brabois (Vandoeuvre-les-Nancy)
    Nancy, France
  • Hôpital Européen Georges-Pompidou
    Paris, France
  • Hôpital Tenon
    Paris, France
  • Hospices Civils de Lyon
    Pierre-Bénite, France
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Oct 2020, 19 months.

Of 127 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 19 months is below that.

Counting every sponsor, half of 266 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2019
First posted
Sep 25, 2019
StartActual
Mar 6, 2019
Primary completionActual
Oct 30, 2020
CompletionActual
Mar 19, 2021
Last update
Jun 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04102553
Lead sponsor
ABX advanced biochemical compounds GmbH
Responsible party
Sponsor
First posted
Sep 25, 2019
Start date
Mar 6, 2019
Primary completion
Oct 30, 2020
Completion
Mar 19, 2021
Last update
Jun 29, 2021

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PSMA-1007 F-18

Start the discussion